JP2018504122A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504122A5
JP2018504122A5 JP2017539018A JP2017539018A JP2018504122A5 JP 2018504122 A5 JP2018504122 A5 JP 2018504122A5 JP 2017539018 A JP2017539018 A JP 2017539018A JP 2017539018 A JP2017539018 A JP 2017539018A JP 2018504122 A5 JP2018504122 A5 JP 2018504122A5
Authority
JP
Japan
Prior art keywords
ifn
item
cells
inflammation
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017539018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/014942 external-priority patent/WO2016123117A1/en
Publication of JP2018504122A publication Critical patent/JP2018504122A/ja
Publication of JP2018504122A5 publication Critical patent/JP2018504122A5/ja
Priority to JP2020201293A priority Critical patent/JP7304844B2/ja
Priority to JP2023025696A priority patent/JP2023062155A/ja
Withdrawn legal-status Critical Current

Links

JP2017539018A 2015-01-26 2016-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 Withdrawn JP2018504122A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020201293A JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107517P 2015-01-26 2015-01-26
US62/107,517 2015-01-26
US201562112653P 2015-02-06 2015-02-06
US62/112,653 2015-02-06
PCT/US2016/014942 WO2016123117A1 (en) 2015-01-26 2016-01-26 Cells with increased immuno-regulatory properties and methods for their use and manufacture

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020201293A Division JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201294A Division JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Publications (2)

Publication Number Publication Date
JP2018504122A JP2018504122A (ja) 2018-02-15
JP2018504122A5 true JP2018504122A5 (https=) 2019-03-07

Family

ID=56544240

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539018A Withdrawn JP2018504122A (ja) 2015-01-26 2016-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201294A Pending JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201293A Active JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023010327A Pending JP2023052658A (ja) 2015-01-26 2023-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A Pending JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020201294A Pending JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201293A Active JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023010327A Pending JP2023052658A (ja) 2015-01-26 2023-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A Pending JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Country Status (7)

Country Link
US (6) US20180112180A1 (https=)
EP (2) EP3250682A4 (https=)
JP (5) JP2018504122A (https=)
CN (2) CN107429232B (https=)
AU (3) AU2016211688A1 (https=)
CA (1) CA2974903A1 (https=)
WO (1) WO2016123117A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
CN107714717A (zh) * 2017-10-11 2018-02-23 刘志强 聚肌胞苷酸在制备治疗或预防结肠炎的药物中的应用
EP4130252A1 (en) * 2018-02-16 2023-02-08 NextCell Pharma AB Composition of allogeneic mesenchymal stem cells
CN113164523A (zh) * 2018-10-10 2021-07-23 北卡罗莱纳州立大学 呈现pd-l1的血小板逆转新发1型糖尿病
BR112021006885A2 (pt) * 2018-10-12 2021-07-13 Salk Institute For Biological Studies células, ilhotas e organoides que escapam da detecção de imunidade e autoimunidade, métodos de produção e uso dos mesmos
CN109706180A (zh) * 2019-01-11 2019-05-03 杭州荣泽生物科技有限公司 一种脐带间充质干细胞过表达ido增强免疫抑制的方法及应用
CN113710796A (zh) * 2019-02-09 2021-11-26 美国卫生和人力服务部 作为减少或预防转移、治疗自身免疫和炎性病症以及重新平衡免疫环境和失调的小生境的平台的基因修饰的造血干细胞和祖细胞(hspc)及间充质细胞
WO2021007180A1 (en) * 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
WO2021167770A1 (en) * 2020-02-18 2021-08-26 Octagon Therapeutics, Inc. Immune cell modulators
EP4171589A4 (en) * 2020-06-26 2024-07-17 The Children's Medical Center Corporation Methods and compositions for treating multiple sclerosis
WO2022011010A1 (en) * 2020-07-08 2022-01-13 The Jackson Laboratory Transgenic mouse model expressing human hla-a201 restriction gene
EP4318077A1 (en) 2021-03-24 2024-02-07 Canon Kabushiki Kaisha Virtual image optical system, virtual image display device provided therewith, and vehicle-mounted system
KR20220162394A (ko) * 2021-06-01 2022-12-08 에스씨엠생명과학 주식회사 기능강화 줄기세포 및 조절 t 세포를 포함하는 아토피 피부염 예방 또는 치료용 병용투여 조성물
WO2025043075A1 (en) * 2023-08-24 2025-02-27 The Johns Hopkins University Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
WO2025199431A1 (en) * 2024-03-22 2025-09-25 Colorado State University Research Foundation Innate immune pathway activated mesenchymal stromal cells for treatment of musculoskeletal disorders or conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
CA2483451C (en) * 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US20060292618A1 (en) * 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
CA2913024A1 (en) * 2006-11-03 2008-05-08 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
US20090324609A1 (en) * 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
ES2799897T3 (es) 2007-08-31 2020-12-22 Whitehead Inst Biomedical Res Estimulación de la vía wnt en la reprogramación de células somáticas
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
RU2573912C2 (ru) * 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
CN108379292A (zh) 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
RS53257B2 (sr) * 2009-07-24 2018-06-29 Immune Design Corp Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
CA2777720C (en) 2009-10-16 2020-10-06 The Scripps Research Institute Induction of pluripotent cells
US20120251514A1 (en) * 2009-11-13 2012-10-04 University Health Network Modulated programmed death ligand-1
AU2010341703B2 (en) * 2009-12-08 2016-01-21 The Board Of Trustees Of The University Of Illinois Stem cell immune modulation methods of use and apparatus
KR20130010121A (ko) * 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
MX374075B (es) * 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
ES2654994T3 (es) * 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
US20140234373A1 (en) * 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
JP6220791B2 (ja) * 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
US20180214487A1 (en) * 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses

Similar Documents

Publication Publication Date Title
JP2018504122A5 (https=)
JP2021050220A5 (https=)
JP7304844B2 (ja) 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2017136094A5 (https=)
JP6396544B2 (ja) エクトインの治療的使用
KR20150053982A (ko) 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법
JP2015504313A5 (https=)
US8829024B2 (en) Combination steroid and glucocorticoid receptor antagonist therapy
JP2023030116A (ja) 内皮機能不全及び炎症の疾患の治療
Etra et al. Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD
JP2019529472A5 (https=)
JP2024533034A5 (https=)
JP6363950B2 (ja) 骨芽細胞機能を増加させる方法
JP2019055913A (ja) ビタミンｄ活性を有するリトコール酸誘導体
KR102596422B1 (ko) 줄기세포의 염증부위로의 이동능 강화방법
US20040248863A1 (en) Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflamation
HK40046349A (en) Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP4346816A2 (en) Compounds for use in a method for treating an autoimmune and inflammatory disease